The global fertility test market size reached USD 584.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 971.7 Million by 2033, exhibiting a growth rate (CAGR) of 5.52% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 584.4 Million |
Market Forecast in 2033 | USD 971.7 Million |
Market Growth Rate (2025-2033) | 5.52% |
Fertility tests are performed to diagnose problems that prevent couples from conceiving. They comprise blood tests, pelvic examination, semen analysis, basal body temperature (BBT) charting, post coital test, transvaginal (pelvic) ultrasound exam, hysterosalpingogram or HSG, hysteroscopy, and laparoscopy. They are reliable, valid, and assist in determining a suitable treatment. In addition, they prevent the spread of sexually transmitted infections (STIs) in the body. Fertility tests also help detect cervical cancer and abnormal cells around the cervix. As a result, they are carried out in hospitals, home care, and fertility clinics.
The growing prevalence of diseases, such as polycystic ovary syndrome (PCOS), due to the overproduction of estrogen by the ovaries represents one of the key factors driving the market. Moreover, there is a rise in infertility rates across the globe due to lifestyle changes and increasing stress and obesity, which is caused by a lack of physical exercise and alterations in dietary pattern. This, along with the increasing awareness among the masses about the benefits of fertility tests, is propelling the growth of the market. In addition, the launch of technologically advanced products to treat infertility among the masses is positively influencing the market. Besides this, key market players are extensively investing in research and development (R&D) activities to introduce pregnancy and ovulation test kits for centralizing all fertility-related data. This, coupled with the burgeoning healthcare industry, is offering lucrative growth opportunities to industry investors. Apart from this, there is an increase in the demand for easy-to-use fertility monitors with high accuracy. The rising utilization of artificial intelligence (AI) in sperm analysis is expected to bolster the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global fertility test market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product, mode of purchase, application and end user.
Breakup by Product:
Breakup by Mode of Purchase:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AdvaCare Pharma, Ava AG, Babystart Ltd. (Snowden Healthcare), Church & Dwight Co. Inc., Fairhaven Health LLC, Geratherm Medical AG, Prestige Consumer Healthcare Inc., Quidel Corporation, UEBE Medical GmbH, Valley Electronics AG and viO HealthTech Limited.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product, Mode of Purchase, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, AdvaCare Pharma, Ava AG, Babystart Ltd. (Snowden Healthcare), Church & Dwight Co. Inc., Fairhaven Health LLC, Geratherm Medical AG, Prestige Consumer Healthcare Inc., Quidel Corporation, UEBE Medical GmbH, Valley Electronics AG and viO HealthTech Limited. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global fertility test market was valued at USD 584.4 Million in 2024.
We expect the global fertility test market to exhibit a CAGR of 5.52% during 2025-2033.
The rising prevalence of Polycystic Ovary Syndrome (PCOS), along with the increasing stress and obesity among female working population, owing to their hectic lifestyles, is primarily driving the global fertility test market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of numerous elective fertility tests for reducing the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals or medical devices.
Based on the product, the global fertility test market has been divided into ovulation prediction kits, fertility monitors, and male fertility testing products. Currently, ovulation prediction kits exhibit a clear dominance in the market.
Based on the mode of purchase, the global fertility test market can be categorized into OTC-based and prescription-based, where OTC-based accounts for the majority of the global market share.
Based on the application, the global fertility test market has been segregated into female fertility testing and male fertility testing. Currently, female fertility testing currently holds the largest market share.
Based on the end user, the global fertility test market can be bifurcated into hospitals, home care settings, fertility clinics, and others. Among these, home care settings exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global fertility test market include Abbott Laboratories, AdvaCare Pharma, Ava AG, Babystart Ltd. (Snowden Healthcare), Church & Dwight Co. Inc., Fairhaven Health LLC, Geratherm Medical AG, Prestige Consumer Healthcare Inc., Quidel Corporation, UEBE Medical GmbH, Valley Electronics AG, and viO HealthTech Limited.